Skip to main content
Clinical Trials/NCT03375060
NCT03375060
Completed
Not Applicable

Optimizing Patient Outcomes Through Early Detection of Uncontrolled Acid Reflux After Endoscopic Therapy in Barrett's Esophagus

Northwestern University1 site in 1 country65 target enrollmentAugust 2, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Esophageal Reflux
Sponsor
Northwestern University
Enrollment
65
Locations
1
Primary Endpoint
Composite histologic score of neosquamous epithelium following endoscopic eradication therapy (EET)
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

This study is looking at a cohort of patients who have undergone treatment for Barrett's Esophagus (BE) and who have experienced complete eradication of the disease. The aim of the proposed study is to evaluate the histologic features of the neosquamous epithelium (NSE) following complete eradication of intestinal metaplasia (CE-IM) in patients undergoing routine surveillance biopsies and compare these data to a direct measure of reflux using 24hr pH impedance, to determine the correlation between histology and persistent reflux. These data will allow us to more accurately risk stratify patients for recurrence of BE following EET.

Registry
clinicaltrials.gov
Start Date
August 2, 2017
End Date
November 5, 2017
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • - Patients who have undergone endoscopic eradication therapy and 24hr pH impedance testing as part of standard of care between 2009 and
  • - Individuals who have signed a consent to be part of the Prospective Evaluation of Barrett's Esophagus Study population.

Exclusion Criteria

  • - Individuals who are not yet adults (infants, children and teenagers), pregnant women and prisoners will be excluded from the study.
  • - Patient who were previously unable or unwilling to give consent to the Prospective Evaluation of Barrett's Esophagus Study will be excluded.

Outcomes

Primary Outcomes

Composite histologic score of neosquamous epithelium following endoscopic eradication therapy (EET)

Time Frame: 1 year

A composite histologic score made up of the following criteria: * Eosinophil infiltration (0: none, 1: scattered or focal, 2: diffuse or multifocal) * Dilated intercellular spaces (0: none, 0.5: intercellular spaces seen at 40x focal, 1: intercellular spaces seen at 40x diffuse, 1.5: intercellular spaces seen at 10x focal, 2: intercellular spaces seen at 10x diffuse) * Parakaratosis (0: absent, 2: present) * Ballooning degeneration (0: none, 1: focal, 2: extensive) * Basal cell hyperplasia (0: \<15% of total thickness, 1: 15-33% of total thickness, 1.5: 33-66% of total thickness, 2: \>66% of total thickness) * Columnar differentiation (0: no columnar mucosa present, 2: columnar mucosa adjacent to squamous) * Ulceration/erosion (0: absent, 1: present) Total possible score: 13

Secondary Outcomes

  • 24hr pH-impedance testing: Demeester score(1 year)
  • Correlation between histologic features and persistent reflux(1 year)
  • 24hr pH-impedance testing: percent acid reflux(1 year)
  • 24hr pH-impedance testing: baseline impedance(1 year)
  • Recurrence rate of intestinal metaplasia (Barrett's esophagus)(1 year)

Study Sites (1)

Loading locations...

Similar Trials